AstraZeneca ADR Representing 0.5 Stock
StockStockPrice
Historical dividends and forecast
AstraZeneca ADR Representing 0.5 has so far distributed $1.485 in 2024. The next dividend will be paid on 25.03.2025
CHART BY
Frequently asked questions
What is AstraZeneca ADR Representing 0.5's market capitalization?
What is AstraZeneca ADR Representing 0.5's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for AstraZeneca ADR Representing 0.5?
What are the analyst ratings and target price for AstraZeneca ADR Representing 0.5's stock?
What is AstraZeneca ADR Representing 0.5's revenue over the trailing twelve months?
What is the EBITDA for AstraZeneca ADR Representing 0.5?
What is the free cash flow of AstraZeneca ADR Representing 0.5?
What is the 5-year beta of AstraZeneca ADR Representing 0.5's stock?
How many employees does AstraZeneca ADR Representing 0.5 have, and what sector and industry does it belong to?
What is the free float of AstraZeneca ADR Representing 0.5's shares?
Financials
Market Cap
$198.15B5Y beta
0.39EPS (TTM)
$4.087Free Float
1.50BP/E ratio (TTM)
31.28Revenue (TTM)
$48.67BEBITDA (TTM)
$15.29BFree Cashflow (TTM)
$2.48BPricing
Analyst Ratings
The price target is $164.75 and the stock is covered by 30 analysts.
Buy
24
Hold
5
Sell
1
Information
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
89,900
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker